A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations.Gregory J. Riely, Rafael Rosell, Robert C. Doebele et al.|Journal of Clinical Oncology|2012Cited by 42
Prävention, Diagnostik, Therapie und Nachsorge des LungenkarzinomsWolfgang Schütte, Dag Wormanns, S Gütz et al.|Pneumologie|2023Cited by 9